Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

SanBio Company Limited SNBIF OTC

Other OTC • Healthcare • Biotechnology • JP • USD

SharesGrow Score
34/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

SanBio Company Limited (SNBIF) is a Biotechnology company in the Healthcare sector, currently trading at $16.45. It has a SharesGrow Score of 32/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $3.8B (loss), growing at +3.4%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $1.2B against $13.6B equity (Debt-to-Equity (D/E) ratio 0.09, conservative). Current ratio is 28.99 (strong liquidity). Debt-to-assets is 7.9%. Total assets: $15.6B.

Analyst outlook: 0 / 1 analysts rate SNBIF as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 45/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 40/100 (Fail), Future 20/100 (Fail), Income ?/100 (Fail).

SNBIF SharesGrow Score Overview

43/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 45/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 20/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SNBIF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
45/100
SNBIF: +0%/yr revenue is, +3.4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet SNBIF: Debt-to-Equity (D/E) ratio 0.09 (conservative), Current ratio is 28.99 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
SNBIF: Gross margin is 0% (+0 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
20/100
Analyst outlook: 0 / 1 analysts rate SNBIF as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range3.85-16.45
Volume1K
Avg Volume (30D)387
Market Cap$1.28B
Beta (1Y)0.27
Share Statistics
EPS (TTM)-52.63
Shares Outstanding$73.12M
IPO Date2015-10-12
Employees29
CEOKeita Mori
Financial Highlights & Ratios
Gross Profit$-8.05M
EBITDA$-3.79B
Net Income$-3.84B
Operating Income$-3.79B
Total Cash$15.08B
Total Debt$1.24B
Net Debt$-13.84B
Total Assets$15.62B
Price / Earnings (P/E)-0.3
Analyst Forecast
Rating ConsensusSell
Analysts Covering1
Buy 0% Hold 0% Sell 100%
Company Info
CountryJP
ExchangeOther OTC
CurrencyUSD
ISINJP3336750009

Price Chart

Track all markets on TradingView
SNBIF
SanBio Company Limited ↗  ·  Other OTC
Healthcare • Biotechnology
3.85 52WK RANGE 16.45

People Also View

ASND
ASND
Ascendis Pharma A/S
$241.71
-3.25%
 CYTK
CYTK
Cytokinetics, Incorporated
$65.37
-1.48%
 LEGN
LEGN
Legend Biotech Corporation
$20.52
+9.79%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.70
+1.63%
 ALEC
ALEC
Alector, Inc.
$2.58
+7.05%
 LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message